Adam Luginbuhl, MD

Trials

Studies that name Adam Luginbuhl, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:35 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT03854032 · Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

  Thomas Jefferson University · terminated · Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx · principal investigator
• Early Ph1
  NCT03238365 · Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Lip, Oral Cavity and Pharynx, Larynx · principal investigator
• Early Ph1
  NCT03109873 · Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer

  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Larynx, Lip, Oral Cavity · principal investigator
• Early Ph1
  NCT02467738 · Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer

  Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · completed · Recurrent Head and Neck Carcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 20:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.